|
US7646707B2
(en)
*
|
2003-12-23 |
2010-01-12 |
At&T Intellectual Property I, L.P. |
Method and system for automatically renaming logical circuit identifiers for rerouted logical circuits in a data network
|
|
US7932382B2
(en)
*
|
2004-01-16 |
2011-04-26 |
The Regents Of The University Of Michigan |
Conformationally constrained Smac mimetics and the uses thereof
|
|
EP1715882A4
(en)
*
|
2004-01-16 |
2009-04-08 |
Univ Michigan |
SMAC-PEPTIDOMIMETIKA AND ITS USES
|
|
RS52545B
(sr)
|
2004-04-07 |
2013-04-30 |
Novartis Ag |
Inhibitori protein apoptoze (iap)
|
|
NZ588799A
(en)
*
|
2004-07-02 |
2012-06-29 |
Genentech Inc |
Inhibitors of iap
|
|
WO2006010118A2
(en)
*
|
2004-07-09 |
2006-01-26 |
The Regents Of The University Of Michigan |
Conformationally constrained smac mimetics and the uses thereof
|
|
EP2457895A1
(en)
*
|
2004-07-12 |
2012-05-30 |
Idun Pharmaceuticals, Inc. |
Tetrapeptide analogs
|
|
ES2475207T3
(es)
*
|
2004-07-15 |
2014-07-10 |
Tetralogic Pharmaceuticals Corporation |
Compuestos de unión a IAP
|
|
DK1836201T4
(da)
|
2004-12-20 |
2013-11-11 |
Genentech Inc |
Pyrrolidininhibitorer af IAP.
|
|
PL1851200T3
(pl)
|
2005-02-25 |
2014-06-30 |
Tetralogic Pharm Corp |
Dimeryczne inhibitory IAP
|
|
EP1883627B1
(en)
|
2005-05-18 |
2018-04-18 |
Pharmascience Inc. |
Bir domain binding compounds
|
|
US20100256046A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
WO2007021825A2
(en)
*
|
2005-08-09 |
2007-02-22 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
KR20080067357A
(ko)
*
|
2005-10-25 |
2008-07-18 |
에게라 쎄라퓨틱스 인코포레이티드 |
Ｉａｐ ｂｉｒ 도메인 결합 화합물
|
|
CA2632807A1
(en)
*
|
2005-12-19 |
2007-09-20 |
Genentech, Inc. |
Inhibitors of iap
|
|
TWI504597B
(zh)
|
2006-03-16 |
2015-10-21 |
Pharmascience Inc |
結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
|
|
WO2007131366A1
(en)
*
|
2006-05-16 |
2007-11-22 |
Aegera Therapeutics Inc. |
Iap bir domain binding compounds
|
|
US20100113326A1
(en)
*
|
2006-07-24 |
2010-05-06 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
US20100056495A1
(en)
*
|
2006-07-24 |
2010-03-04 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
EP2049524A2
(en)
|
2006-07-24 |
2009-04-22 |
Tetralogic Pharmaceuticals Corporation |
Iap inhibitors
|
|
WO2008014263A2
(en)
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap antagonists
|
|
US20100143499A1
(en)
*
|
2006-07-24 |
2010-06-10 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014229A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
PE20110218A1
(es)
|
2006-08-02 |
2011-04-01 |
Novartis Ag |
DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
|
|
AU2007288245A1
(en)
*
|
2006-08-24 |
2008-02-28 |
Novartis Ag |
2- (pyrazin-2-yl) -thiazole and 2- (1h-pyrazol-3-yl) -thiazole derivatives as well as related compounds as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders
|
|
JP5351025B2
(ja)
*
|
2006-09-22 |
2013-11-27 |
ノバルティス アーゲー |
ヘテロ環式有機化合物
|
|
RU2009117701A
(ru)
*
|
2006-10-12 |
2010-11-20 |
Новартис АГ (CH) |
Производные пирролидина в качестве ингибиторов iap
|
|
CN101605786A
(zh)
*
|
2006-12-19 |
2009-12-16 |
健泰科生物技术公司 |
细胞凋亡抑制剂的咪唑并吡啶抑制剂
|
|
MX2009006728A
(es)
*
|
2006-12-20 |
2009-09-09 |
Novartis Ag |
Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
|
|
EP2079309B1
(en)
*
|
2007-04-12 |
2015-11-11 |
Joyant Pharmaceuticals Inc |
SMAC MIMEE DIMERS AND TRIMERS USEFUL AS ANTICANCER AGENTS
|
|
TWI432212B
(zh)
|
2007-04-30 |
2014-04-01 |
Genentech Inc |
Ｉａｐ抑制劑
|
|
US20110008802A1
(en)
*
|
2007-05-07 |
2011-01-13 |
Tetralogic Pharmaceuticals Corp. |
TNFalpha GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS
|
|
WO2008144925A1
(en)
*
|
2007-05-30 |
2008-12-04 |
Aegera Therapeutics Inc. |
Iap bir domain binding compounds
|
|
AU2009203971A1
(en)
*
|
2008-01-11 |
2009-07-16 |
Genentech, Inc. |
Inhibitors of IAP
|
|
WO2009136290A1
(en)
*
|
2008-05-05 |
2009-11-12 |
Aegera Therapeutics, Inc. |
Functionalized pyrrolidines and use thereof as iap inhibitors
|
|
WO2009155709A1
(en)
*
|
2008-06-27 |
2009-12-30 |
Aegera Therapeutics Inc. |
Bridged secondary amines and use thereof as iap bir domain binding compounds
|
|
JP2011529962A
(ja)
*
|
2008-08-02 |
2011-12-15 |
ジェネンテック， インコーポレイテッド |
Ｉａｐのインヒビター
|
|
WO2010021934A2
(en)
*
|
2008-08-16 |
2010-02-25 |
Genentech, Inc. |
Azaindole inhibitors of iap
|
|
AU2009293403A1
(en)
|
2008-09-17 |
2010-03-25 |
Tetralogic Pharmaceuticals Corp. |
IAP inhibitors
|
|
FR2939073B1
(fr)
|
2008-12-03 |
2010-12-31 |
Sidel Participations |
Formage des recipients avec contre-pression localisee
|
|
US20100317593A1
(en)
*
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
|
US8283372B2
(en)
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
|
CN102612651A
(zh)
|
2009-09-18 |
2012-07-25 |
诺瓦提斯公司 |
Iap抑制剂化合物的生物标志物
|
|
JP5529282B2
(ja)
|
2009-10-28 |
2014-06-25 |
ジョイアント ファーマスーティカルズ、インク． |
二量体Ｓｍａｃ模倣薬
|
|
CN102050867A
(zh)
*
|
2009-11-10 |
2011-05-11 |
上海艾力斯医药科技有限公司 |
四肽类似物、制备方法及其应用
|
|
SG182724A1
(en)
*
|
2010-02-12 |
2012-08-30 |
Pharmascience Inc |
Iap bir domain binding compounds
|
|
ES2651002T3
(es)
|
2010-04-16 |
2018-01-23 |
Bayer Intellectual Property Gmbh |
Nuevos compuestos heterocíclicos como pesticidas
|
|
GB201106817D0
(en)
|
2011-04-21 |
2011-06-01 |
Astex Therapeutics Ltd |
New compound
|
|
WO2013043591A1
(en)
*
|
2011-09-21 |
2013-03-28 |
Albert Einstein College Of Medicine Of Yeshiva University |
Combination therapy for cancer
|
|
CA2850330A1
(en)
|
2011-09-30 |
2013-04-04 |
Tetralogic Pharmaceuticals Corporation |
Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
|
|
NO2755614T3
(enExample)
*
|
2012-01-03 |
2018-03-31 |
|
|
|
CN104284988A
(zh)
|
2012-05-04 |
2015-01-14 |
诺华股份有限公司 |
用于iap抑制剂治疗的生物标记
|
|
JP6382831B2
(ja)
|
2012-11-30 |
2018-08-29 |
サンフォード−バーンハム メディカル リサーチ インスティテュート |
アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
CN105007950B
(zh)
|
2013-03-15 |
2019-01-15 |
诺华股份有限公司 |
抗体药物缀合物
|
|
EP3013329B1
(en)
|
2013-06-25 |
2020-08-05 |
The Walter and Eliza Hall Institute of Medical Research |
Smac mimetics for the treatment of persistent intracellular hbv infection
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
SG10201808102WA
(en)
|
2013-12-20 |
2018-10-30 |
Astex Therapeutics Ltd |
Bicyclic heterocycle compounds and their uses in therapy
|
|
US10441654B2
(en)
|
2014-01-24 |
2019-10-15 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
SMC combination therapy for the treatment of cancer
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US9811383B2
(en)
*
|
2014-05-05 |
2017-11-07 |
Empire Technology Development Llc |
Processing a composite task based on a semantic relation graph
|
|
CA2950911C
(en)
|
2014-06-04 |
2023-10-10 |
Sanford-Burnham Medical Research Institute |
Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
EA201790334A1
(ru)
|
2014-08-12 |
2017-06-30 |
Новартис Аг |
Конъюгаты анти-cdh6 антитела с лекарственным средством
|
|
GB201414730D0
(en)
|
2014-08-19 |
2014-10-01 |
Tpp Global Dev Ltd |
Pharmaceutical compound
|
|
WO2016079527A1
(en)
|
2014-11-19 |
2016-05-26 |
Tetralogic Birinapant Uk Ltd |
Combination therapy
|
|
WO2016097773A1
(en)
|
2014-12-19 |
2016-06-23 |
Children's Cancer Institute |
Therapeutic iap antagonists for treating proliferative disorders
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
MX390189B
(es)
|
2015-01-20 |
2025-03-20 |
Arvinas Operations Inc |
COMPUESTOS Y METODOS PARA LA DEGRADACION DIRIGIDA DE RECEPTOR DE ANDROGENOs.
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
WO2017030814A1
(en)
|
2015-08-19 |
2017-02-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
CN108430515B
(zh)
|
2015-10-29 |
2021-11-12 |
诺华股份有限公司 |
包含toll-样受体激动剂的抗体缀合物
|
|
WO2017222914A1
(en)
|
2016-06-21 |
2017-12-28 |
Inception 4, Inc. |
Carbocyclic prolinamide derivatives
|
|
CN109476637B
(zh)
|
2016-06-21 |
2022-02-01 |
奥瑞恩眼科有限责任公司 |
杂环脯氨酰胺衍生物
|
|
AU2017367872B2
(en)
|
2016-11-01 |
2022-03-31 |
Arvinas, Inc. |
Tau-protein targeting protacs and associated methods of use
|
|
CN118834201A
(zh)
|
2016-12-01 |
2024-10-25 |
阿尔维纳斯运营股份有限公司 |
作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物
|
|
KR102839545B1
(ko)
|
2016-12-23 |
2025-07-29 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
KR20190101406A
(ko)
|
2016-12-23 |
2019-08-30 |
아비나스 오퍼레이션스, 인코포레이티드 |
Egfr 단백질분해 표적화 키메라 분자 및 관련 사용 방법
|
|
WO2018118598A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
CA3049912A1
(en)
|
2017-01-26 |
2018-08-02 |
Arvinas Operations, Inc. |
Modulators of estrogen receptor proteolysis and associated methods of use
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
US11179413B2
(en)
|
2017-03-06 |
2021-11-23 |
Novartis Ag |
Methods of treatment of cancer with reduced UBB expression
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
IL322309A
(en)
|
2017-05-24 |
2025-09-01 |
Novartis Ag |
IL2 antibody grafted proteins and methods of use in cancer treatment
|
|
CN111107868A
(zh)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
SG11202004377XA
(en)
*
|
2017-11-13 |
2020-06-29 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Smac mimetics used as iap inhibitors and use thereof
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
JP7161849B2
(ja)
*
|
2018-01-24 |
2022-10-27 |
株式会社クラレ |
第一級アミンの製造方法
|
|
WO2019154053A1
(zh)
*
|
2018-02-09 |
2019-08-15 |
广东东阳光药业有限公司 |
Iap抑制剂及其在药物中的应用
|
|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
|
WO2020023851A1
(en)
|
2018-07-26 |
2020-01-30 |
Yale University |
Bifunctional substitued pyrimidines as modulators of fak proteolyse
|
|
JP7297053B2
(ja)
|
2018-08-20 |
2023-06-23 |
アルビナス・オペレーションズ・インコーポレイテッド |
神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
|
|
IL281188B2
(en)
|
2018-09-07 |
2025-08-01 |
Arvinas Operations Inc |
Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
MX2021007392A
(es)
|
2018-12-20 |
2021-08-24 |
Novartis Ag |
Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
|
|
KR20240052881A
(ko)
|
2018-12-21 |
2024-04-23 |
노파르티스 아게 |
Pmel17에 대한 항체 및 이의 접합체
|
|
BR112021015783A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
|
|
WO2020165834A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3936126A4
(en)
*
|
2019-03-07 |
2022-12-21 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
COMBINATION OF IAP INHIBITOR AND IMMUNOCHECK POINT INHIBITOR
|
|
US20220177453A1
(en)
*
|
2019-05-10 |
2022-06-09 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Crystallization of smac mimic used as iap inhibitor and preparation method thereof
|
|
CN114867727B
(zh)
|
2019-07-17 |
2025-02-21 |
阿尔维纳斯运营股份有限公司 |
Tau蛋白靶向化合物及相关使用方法
|
|
US20220257698A1
(en)
|
2019-08-02 |
2022-08-18 |
Lanthiopep B.V. |
Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
|
|
IL290789B2
(en)
|
2019-08-26 |
2025-09-01 |
Arvinas Operations Inc |
Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
|
|
TW202135859A
(zh)
|
2019-12-20 |
2021-10-01 |
瑞士商諾華公司 |
組合療法
|
|
CA3166980A1
(en)
|
2020-01-20 |
2021-07-29 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
CN111205232B
(zh)
*
|
2020-02-26 |
2022-07-01 |
浙江天宇药业股份有限公司 |
一种替格瑞洛中间体的合成方法
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
JP7819176B2
(ja)
|
2020-08-03 |
2026-02-24 |
ノバルティス アーゲー |
ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
US12180193B2
(en)
|
2020-08-28 |
2024-12-31 |
Arvinas Operations, Inc. |
Accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
KR20230069144A
(ko)
|
2020-09-14 |
2023-05-18 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체의 표적화된 분해를 위한 화합물의 결정질 형태
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CA3216880A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
AU2023314354A1
(en)
|
2022-07-26 |
2024-11-21 |
Novartis Ag |
Crystalline forms of an akr1c3 dependent kars inhibitor
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
AU2024212035A1
(en)
|
2023-01-26 |
2025-08-14 |
Arvinas Operations, Inc. |
Cereblon-based kras degrading protacs ans uses related thereto
|